Somatic Mutations of ErbB4

Cancer drugs targeting ErbB receptors, such as epidermal growth factor receptor and ErbB2, are currently in clinical use. However, the role of ErbB4 as a potential cancer drug target has remained controversial. Recently, somatic mutations altering the coding region of ErbB4 were described in patients with breast, gastric, colorectal, or non-small cell lung cancer, but the functional significance of these mutations is unknown. Here we demonstrate that 2 of 10 of the cancer-associated mutations of ErbB4 lead to loss of ErbB4 kinase activity due to disruption of functionally important structural features. Interestingly, the kinase-dead ErbB4 mutants were as efficient as wild-type ErbB4 in forming a heterodimeric neuregulin receptor with ErbB2 and promoting phosphorylation of Erk1/2 and Akt in an ErbB2 kinase-dependent manner. However, the mutant ErbB4 receptors failed to phosphorylate STAT5 and suppressed differentiation of MDA-MB-468 mammary carcinoma cells. These findings suggest that the somatic ErbB4 mutations have functional consequences and lead to selective changes in ErbB4 signaling.

[1]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[2]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[3]  J. Kuriyan,et al.  The Conformational Plasticity of Protein Kinases , 2002, Cell.

[4]  G. Carpenter,et al.  ErbB-4 s80 Intracellular Domain Abrogates ETO2-dependent Transcriptional Repression* , 2006, Journal of Biological Chemistry.

[5]  H. Lane,et al.  ERBB receptors and cancer: the complexity of targeted inhibitors , 2005, Nature Reviews Cancer.

[6]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[7]  Jorma Isola,et al.  Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. , 2005, Molecular biology of the cell.

[8]  B. Beutler,et al.  Velvet, a Dominant Egfr Mutation That Causes Wavy Hair and Defective Eyelid Development in Mice , 2004, Genetics.

[9]  C. Croce,et al.  Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms , 2008, Proceedings of the National Academy of Sciences.

[10]  Xin-Yuan Fu,et al.  Erbb4 Signaling in the Mammary Gland Is Required for Lobuloalveolar Development and Stat5 Activation during Lactation , 1999, The Journal of cell biology.

[11]  Jian Hui Wu,et al.  Impact of EGFR point mutations on the sensitivity to gefitinib: Insights from comparative structural analyses and molecular dynamics simulations , 2006, Proteins.

[12]  K. Lackey,et al.  Comparison of the Biochemical and Kinetic Properties of the Type 1 Receptor Tyrosine Kinase Intracellular Domains , 2002, The Journal of Biological Chemistry.

[13]  Mats Gyllenberg,et al.  BODIL: a molecular modeling environment for structure-function analysis and drug design , 2004, J. Comput. Aided Mol. Des..

[14]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[15]  M. Sliwkowski,et al.  Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.

[16]  Frank E. Jones,et al.  The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone , 2004, The Journal of cell biology.

[17]  Carlos L Arteaga,et al.  HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. , 2006, Cancer cell.

[18]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[19]  Ron Bose,et al.  Mechanism of activation and inhibition of the HER4/ErbB4 kinase. , 2008, Structure.

[20]  A. Citri,et al.  The deaf and the dumb: the biology of ErbB-2 and ErbB-3. , 2003, Experimental cell research.

[21]  M. Mann,et al.  Phosphotyrosine interactome of the ErbB-receptor kinase family , 2005, Molecular systems biology.

[22]  J. Isola,et al.  Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. , 2005, Cancer research.

[23]  K. Shokat,et al.  Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.

[24]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[25]  Tony J. Pircher,et al.  Mitogen-activated protein kinase kinase inhibition decreases growth hormone stimulated transcription mediated by STAT5 , 1997, Molecular and Cellular Endocrinology.

[26]  G. Plowman,et al.  Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[28]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[29]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[30]  Melissa A. Sandahl,et al.  The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. , 2006, Molecular biology of the cell.

[31]  Andrew D. Yates,et al.  Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.

[32]  L. Johnson,et al.  Active and Inactive Protein Kinases: Structural Basis for Regulation , 1996, Cell.

[33]  J. Ptak,et al.  Colorectal cancer: Mutations in a signalling pathway , 2005, Nature.

[34]  W. Gullick.  c‐erbB‐4/HER4: friend or foe? , 2003, The Journal of pathology.

[35]  John Kuriyan,et al.  An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.

[36]  M. Hung,et al.  Survival of cancer cells is maintained by EGFR independent of its kinase activity. , 2008, Cancer cell.

[37]  Sami Kilpinen,et al.  Role of ErbB4 in Breast Cancer , 2008, Journal of Mammary Gland Biology and Neoplasia.

[38]  T. Hunter,et al.  The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. , 1988, Science.

[39]  M. Wasik,et al.  STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression , 2007, Nature Medicine.

[40]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[41]  J. Richardson,et al.  The penultimate rotamer library , 2000, Proteins.

[42]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[43]  Y. Yarden,et al.  Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains , 2007, Oncogene.

[44]  Gerrit Groenhof,et al.  GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..

[45]  Matthew Meyerson,et al.  Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. , 2007, Cancer cell.

[46]  W. Park,et al.  Somatic mutations of the ERBB4 kinase domain in human cancers , 2006, International journal of cancer.